A Phase II and Pharmacokinetic Study of Weekly 72-h Topotecan Infusion in Patients with Platinum-Resistant and Paclitaxel-Resistant Ovarian Carcinoma
- 1 August 2000
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 78 (2) , 228-234
- https://doi.org/10.1006/gyno.2000.5844
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.Journal of Clinical Oncology, 1998
- Topotecan in Platinum- and Paclitaxel-Resistant Ovarian CancerGynecologic Oncology, 1997
- 537: A phase II study of topotecan given as a continuous 21-day infusion every 28 days in platinum pre-treated ovarian carcinomaEuropean Journal Of Cancer, 1997
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal of Clinical Oncology, 1997
- Phase I and pharmacologic study of topotecan in patients with impaired renal function.Journal of Clinical Oncology, 1996
- Clinical Pharmacokinetics of TopotecanClinical Pharmacokinetics, 1996
- Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.Journal of Clinical Oncology, 1994
- Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusionAnti-Cancer Drugs, 1994
- Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In VitroJNCI Journal of the National Cancer Institute, 1992
- High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasmaJournal of Pharmaceutical and Biomedical Analysis, 1990